CRISPR Therapeutics details CTX310 reduction data, names new CTO and CFO

CRISPR Therapeutics AG reported Q3 2026 results and business updates in a release dated November 2, 2026, adding new clinical detail on its cardiovascular gene-editing candidate CTX310. In August, CRISPR Therapeutics presented Phase 1a durability data for CTX310 in a late-breaking session at the European Society of Cardiology Congress 2026 and simultaneously published in The New England Journal of Medicine, showing that a single course treatment produced deep and durable reductions in circulating ANGPTL3, triglycerides, and low-density lipoprotein that were sustained through one year of follow-up.¹ At the highest dose, mean reductions from baseline were 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C in a mixed patient cohort with high triglycerides, high LDL-C, or both, and CTX310 was well tolerated with no treatment-related serious adverse events.¹

Following that data, the FDA granted Regenerative Medicine Advanced Therapy designations to CTX310 for severe hypertriglyceridemia and for elevated LDL-C, a designation that provides the benefits of Fast Track and Breakthrough Therapy designations, including early interactions with the FDA and potential eligibility for priority review and accelerated approval.¹ Phase 1b data in patients with severe hypertriglyceridemia is scheduled for a late-breaking oral presentation at the American Heart Association Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT.¹

On leadership, CRISPR Therapeutics announced the appointment of Sivakesava Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately, bringing more than 30 years of technical operations and quality leadership across biologics, vaccines, oligonucleotides, RNA therapeutics, and LNP delivery, most recently as Chief Technical Officer at Orna Therapeutics.¹ In October, the company also announced the appointment of A.J. Silver, its Senior Vice President of Finance, as Chief Financial Officer, effective October 19, 2026, succeeding Raju Prasad, Ph.D., who stepped down to pursue external opportunities.¹

CASGEVY commercial growth continued, with third quarter 2026 revenue of $99 million, representing 30% growth quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025.¹ Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025, with the increase primarily driven by net proceeds of $585.4 million from convertible senior notes issued in March 2026, offset by operating expenses.¹